3-吡啶甲胺,N-乙基-α-甲基-,(-)-(9CI) | 5746-54-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-吡啶甲胺,N-乙基-α-甲基-,(-)-(9CI)
• 中文别名: N-乙基-alpha-甲基-3-吡啶甲胺
• 英文名称: ethyl-(1-pyridin-3-yl-ethyl)-amine
• 英文别名: ethyl-(1-[3]pyridyl-ethyl)-amine；Aethyl-(1-[3]pyridyl-aethyl)-amin；3-(1-Ethylamino-ethyl)-pyridin；N-Ethyl-1-(pyridin-3-yl)ethan-1-amine；N-ethyl-1-pyridin-3-ylethanamine
• CAS: 5746-54-3；130343-03-2；130343-04-3
• 化学式: C₉H₁₄N₂
• mdl: MFCD09941689
• 分子量: 150.224
• InChiKey: DKNOPKLVHKNERI-UHFFFAOYSA-N

物化性质

• 沸点：
  229.3±15.0 °C(Predicted)
• 密度：
  0.950±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  三氟乙酸酐 、 3-吡啶甲胺,N-乙基-α-甲基-,(-)-(9CI) 、 二氯甲烷 生成 N-ethyl-2,2,2-trifluoro-N-(1-pyridin-3-ylethyl)acetamide
  参考文献：
  名称：

  ARMSTRONG, DANIEL W.;LI, WEIYONG;STALCUP, APRYLL M.;SECOR, HENRY V.;IZAC,+, ANAL. CHIM. ACTA , 234,(1990) N, C. 365-380

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(3-吡啶)乙胺 、 碘乙烷 在 乙醇 作用下， 生成 3-吡啶甲胺,N-乙基-α-甲基-,(-)-(9CI)
  参考文献：
  名称：

  La Forge, Journal of the American Chemical Society, 1928, vol. 50, p. 2482

  摘要：

  DOI：

文献信息

• [EN] CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE<br/>[FR] COMPOSÉS CONTENANT DE L'ACIDE CARBOXYLIQUE UTILISÉS EN TANT QUE MODULATEURS DE LA BIS-PHOSPHOGLYCÉRATE MUTASE POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE
  申请人：GENZYME CORP

  公开号：WO2022056447A1

  公开（公告）日：2022-03-17

  Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.

  本文提供了用于调节双磷酸甘油酸变异酶（BPGM）以治疗镰状细胞贫血的化合物和其组合物。
• Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20070269405A1

  公开（公告）日：2007-11-22

  Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR），在增强肌肉张力和治疗由雄激素缺乏引起的或可以通过雄激素治疗改善的疾病中有用，包括骨质疏松症，骨质疏松症，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建手术后的骨损伤，肌肉萎缩，虚弱，老化皮肤，男性性腺功能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖症，再生障碍性贫血和其他造血系统疾病，炎性关节炎和关节修复，艾滋病浪费，前列腺癌，良性前列腺增生症（BPH），腹部脂肪堆积，代谢综合征，2型糖尿病，癌症恶病质，阿尔茨海默病，肌肉萎缩症，认知能力下降，性功能障碍，睡眠呼吸暂停，抑郁症，早发卵巢衰竭和自身免疫疾病，单独或与其他活性药物联合使用。
• 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS
  申请人：Tsou Hwei-Ru

  公开号：US20100068204A1

  公开（公告）日：2010-03-18

  Compounds of the formula I and pharmaceutically acceptable salts thereof, wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are defined as set forth herein are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds of the invention and a pharmaceutically acceptable carrier, methods of making the compounds of the invention and methods of using the compounds for inhibiting mTOR and PI3 kinases and for treating cancers.

  本文披露了化学式I及其药学上可接受的盐的化合物，其中A、B、R1、R2、R3、R4、R5、R6和R7的定义如本文所述。本文还披露了包含本发明化合物和药学上可接受的载体的制药组合物，制备本发明化合物的方法以及使用本化合物抑制mTOR和PI3激酶并治疗癌症的方法。
• Nuclear Transport Modulators and Uses Thereof
  申请人：Sandanayaka Vincent P.

  公开号：US20150018332A1

  公开（公告）日：2015-01-15

  The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  本发明通常涉及核转运调节剂，例如CRM1抑制剂，更具体地涉及公式（I）所表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述。本发明还包括合成和使用结构式（I）的化合物，或其药学上可接受的盐或组合物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况中的使用。
• Nuclear transport modulators and uses thereof
  申请人：Sandanayaka Vincent P.

  公开号：US09428490B2

  公开（公告）日：2016-08-30

  The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  本发明通常涉及核运输调节剂，例如CRM1抑制剂，更具体地涉及由公式（I）表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述的那样。本发明还包括合成和使用结构式（I）的化合物，或其药学上可接受的盐或组成物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况中的应用。